159 related articles for article (PubMed ID: 22233925)
1. The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer.
Coley HM; Safuwan NA; Chivers P; Papacharalbous E; Giannopoulos T; Butler-Manuel S; Madhuri K; Lovell DP; Crook T
Br J Cancer; 2012 Jan; 106(3):482-9. PubMed ID: 22233925
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer.
Pateras IS; Apostolopoulou K; Koutsami M; Evangelou K; Tsantoulis P; Liloglou T; Nikolaidis G; Sigala F; Kittas C; Field JK; Kotsinas A; Gorgoulis VG
Int J Cancer; 2006 Dec; 119(11):2546-56. PubMed ID: 16988944
[TBL] [Abstract][Full Text] [Related]
3. Significance of p57(Kip2) down-regulation in oncogenesis of bladder carcinoma: an immunohistochemical study.
Bozdoğan O; Atasoy P; Batislam E; Başar MM; Başar H
Tumori; 2008; 94(4):556-62. PubMed ID: 18822693
[TBL] [Abstract][Full Text] [Related]
4. The cyclin-dependent kinase inhibitor p57Kip2 regulates cell cycle exit, differentiation, and migration of embryonic cerebral cortical precursors.
Tury A; Mairet-Coello G; DiCicco-Bloom E
Cereb Cortex; 2011 Aug; 21(8):1840-56. PubMed ID: 21245411
[TBL] [Abstract][Full Text] [Related]
5. The KIP/CIP family members p21^{Waf1/Cip1} and p57^{Kip2} as diagnostic markers for breast cancer.
Zohny SF; Baothman OA; El-Shinawi M; Al-Malki AL; Zamzami MA; Choudhry H
Cancer Biomark; 2017; 18(4):413-423. PubMed ID: 28106536
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of p57kip² promotes cell invasion via LIMK/cofilin pathway in human nasopharyngeal carcinoma cells.
Chow SE; Wang JS; Lin MR; Lee CL
J Cell Biochem; 2011 Nov; 112(11):3459-68. PubMed ID: 21769918
[TBL] [Abstract][Full Text] [Related]
7. Cyclic changes in the expression of p57(kip2) in human endometrium and its regulation by steroid hormones in endometrial stromal cells in vitro.
Kim ST; Lee SK; Gye MC
Reprod Sci; 2012 Jan; 19(1):92-101. PubMed ID: 22064387
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.
Meier JC; Haendler B; Seidel H; Groth P; Adams R; Ziegelbauer K; Kreft B; Beckmann G; Sommer A; Kopitz C
Cancer Med; 2015 Feb; 4(2):253-67. PubMed ID: 25490861
[TBL] [Abstract][Full Text] [Related]
9. Expressions of cyclin E, cyclin dependent kinase 2 and p57(KIP2) in human gastric cancer.
Liang B; Wang S; Yang X; Ye Y; Yu Y; Cui Z
Chin Med J (Engl); 2003 Jan; 116(1):20-3. PubMed ID: 12667381
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors.
Lu Z; Hunter T
Cell Cycle; 2010 Jun; 9(12):2342-52. PubMed ID: 20519948
[TBL] [Abstract][Full Text] [Related]
11. Loss of p27
Kim GJ; Kim DH; Min KW; Kim YH; Oh YH
Pathol Res Pract; 2018 Apr; 214(4):565-571. PubMed ID: 29482985
[TBL] [Abstract][Full Text] [Related]
12. RUNX3 contributes to carboplatin resistance in epithelial ovarian cancer cells.
Barghout SH; Zepeda N; Vincent K; Azad AK; Xu Z; Yang C; Steed H; Postovit LM; Fu Y
Gynecol Oncol; 2015 Sep; 138(3):647-55. PubMed ID: 26186909
[TBL] [Abstract][Full Text] [Related]
13. P21-activated kinase 4 regulates the cyclin-dependent kinase inhibitor p57(kip2) in human breast cancer.
Li Y; Wang D; Zhang H; Wang C; Dai W; Cheng Z; Wang G; Li F
Anat Rec (Hoboken); 2013 Oct; 296(10):1561-7. PubMed ID: 23873832
[TBL] [Abstract][Full Text] [Related]
14. Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer.
Syed N; Coley HM; Sehouli J; Koensgen D; Mustea A; Szlosarek P; McNeish I; Blagden SP; Schmid P; Lovell DP; Hatzimichael E; Crook T
Cancer Res; 2011 May; 71(9):3317-27. PubMed ID: 21402713
[TBL] [Abstract][Full Text] [Related]
15. Distinct developmental roles of cell cycle inhibitors p57Kip2 and p27Kip1 distinguish pituitary progenitor cell cycle exit from cell cycle reentry of differentiated cells.
Bilodeau S; Roussel-Gervais A; Drouin J
Mol Cell Biol; 2009 Apr; 29(7):1895-908. PubMed ID: 19139274
[TBL] [Abstract][Full Text] [Related]
16. Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype.
Li Y; Nagai H; Ohno T; Yuge M; Hatano S; Ito E; Mori N; Saito H; Kinoshita T
Blood; 2002 Oct; 100(7):2572-7. PubMed ID: 12239171
[TBL] [Abstract][Full Text] [Related]
17. Age-dependent changes of p57(Kip2) and p21(Cip1/Waf1) expression in skeletal muscle and lung of mice.
Park CW; Chung JH
Biochim Biophys Acta; 2001 Aug; 1520(2):163-8. PubMed ID: 11513958
[TBL] [Abstract][Full Text] [Related]
18. Periodic expression of the cyclin-dependent kinase inhibitor p57(Kip2) in trophoblast giant cells defines a G2-like gap phase of the endocycle.
Hattori N; Davies TC; Anson-Cartwright L; Cross JC
Mol Biol Cell; 2000 Mar; 11(3):1037-45. PubMed ID: 10712518
[TBL] [Abstract][Full Text] [Related]
19. Identification of multiple cell cycle regulatory functions of p57Kip2 in human T lymphocytes.
Li G; Domenico J; Lucas JJ; Gelfand EW
J Immunol; 2004 Aug; 173(4):2383-91. PubMed ID: 15294951
[TBL] [Abstract][Full Text] [Related]
20. Expression of p21(Wafl/Cip1), p57(Kip2) and HER2/neu in patients with gallbladder cancer.
Puhalla H; Wrba F; Kandioler D; Lehnert M; Huynh A; Gruenberger T; Tamandl D; Filipits M
Anticancer Res; 2007; 27(3B):1679-84. PubMed ID: 17595796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
